Update on the treatment of metastatic castration-resistant prostate cancer (mCRPC) – Certificate of Completion

After completing this module, participants will have enhanced:

1. Knowledge of the different modes of action of metastatic castration-resistant prostate cancer (mCRPC) therapies including new agents;
2. Familiarity with the clinical data on therapies for mCRPC pre- and post-docetaxel chemotherapy, including efficacy, quality of life and safety.
3. Confidence regarding the role of these new medications in pre- and post-chemotherapy management, including when to start and stop treatment.